StemCell Therapy

QY Research has published a new report on the global Targeted Biomarker market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, The analysts have clarified every part of the market exhaustive fastidious research and full focus to each point. This report gives additional information on statistical data to assist readers with understanding the entire market. This report offers a clear understanding of the present as well as future scenario of the global Targeted Biomarker industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Targeted Biomarker production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Targeted Biomarker market include _ bioMerieux, IntegraGen, Myriad Genetics, Protagen, Qiagen, PerkinElmer, Merck Millipore, Bio-Rad Laboratories, Enzo Biochem, EKF Diagnostics, Meso Scale Diagnostics, LLC. Targeted Biomarker Breakdown Data by Type

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1456215/global-targeted-biomarker-market

Segmental Analysis

The report has classified the global Targeted Biomarker industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Targeted Biomarker manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Targeted Biomarker industry.

Global Targeted Biomarker Market Segment By Type:

, Safety biomarker, Efficacy biomarker, Validation biomarker Targeted Biomarker Breakdown Data by Application,

Global Targeted Biomarker Market Segment By Application:

Diagnostics development, Drug discovery & development, Personalized medicine, Disease risk assessment, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Targeted Biomarker industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Targeted Biomarker market include _ bioMerieux, IntegraGen, Myriad Genetics, Protagen, Qiagen, PerkinElmer, Merck Millipore, Bio-Rad Laboratories, Enzo Biochem, EKF Diagnostics, Meso Scale Diagnostics, LLC. Targeted Biomarker Breakdown Data by Type

Key questions answered in the report:

For Discount, COVID-19 Impact, Customization in the Report: https://www.qyresearch.com/customize-request/form/1456215/global-targeted-biomarker-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Targeted Biomarker Revenue1.4 Market Analysis by Type1.4.1 Global Targeted Biomarker Market Size Growth Rate by Type: 2020 VS 20261.4.2 Safety biomarker1.4.3 Efficacy biomarker1.4.4 Validation biomarker1.5 Market by Application1.5.1 Global Targeted Biomarker Market Share by Application: 2020 VS 20261.5.2 Diagnostics development1.5.3 Drug discovery & development1.5.4 Personalized medicine1.5.5 Disease risk assessment1.5.6 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Targeted Biomarker Market Perspective (2015-2026)2.2 Targeted Biomarker Growth Trends by Regions2.2.1 Targeted Biomarker Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Targeted Biomarker Historic Market Share by Regions (2015-2020)2.2.3 Targeted Biomarker Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Targeted Biomarker Market Growth Strategy2.3.6 Primary Interviews with Key Targeted Biomarker Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Targeted Biomarker Players by Market Size3.1.1 Global Top Targeted Biomarker Players by Revenue (2015-2020)3.1.2 Global Targeted Biomarker Revenue Market Share by Players (2015-2020)3.1.3 Global Targeted Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Targeted Biomarker Market Concentration Ratio3.2.1 Global Targeted Biomarker Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Targeted Biomarker Revenue in 20193.3 Targeted Biomarker Key Players Head office and Area Served3.4 Key Players Targeted Biomarker Product Solution and Service3.5 Date of Enter into Targeted Biomarker Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Targeted Biomarker Historic Market Size by Type (2015-2020)4.2 Global Targeted Biomarker Forecasted Market Size by Type (2021-2026) 5 Targeted Biomarker Breakdown Data by Application (2015-2026)5.1 Global Targeted Biomarker Market Size by Application (2015-2020)5.2 Global Targeted Biomarker Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Targeted Biomarker Market Size (2015-2020)6.2 Targeted Biomarker Key Players in North America (2019-2020)6.3 North America Targeted Biomarker Market Size by Type (2015-2020)6.4 North America Targeted Biomarker Market Size by Application (2015-2020) 7 Europe7.1 Europe Targeted Biomarker Market Size (2015-2020)7.2 Targeted Biomarker Key Players in Europe (2019-2020)7.3 Europe Targeted Biomarker Market Size by Type (2015-2020)7.4 Europe Targeted Biomarker Market Size by Application (2015-2020) 8 China8.1 China Targeted Biomarker Market Size (2015-2020)8.2 Targeted Biomarker Key Players in China (2019-2020)8.3 China Targeted Biomarker Market Size by Type (2015-2020)8.4 China Targeted Biomarker Market Size by Application (2015-2020) 9 Japan9.1 Japan Targeted Biomarker Market Size (2015-2020)9.2 Targeted Biomarker Key Players in Japan (2019-2020)9.3 Japan Targeted Biomarker Market Size by Type (2015-2020)9.4 Japan Targeted Biomarker Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Targeted Biomarker Market Size (2015-2020)10.2 Targeted Biomarker Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Targeted Biomarker Market Size by Type (2015-2020)10.4 Southeast Asia Targeted Biomarker Market Size by Application (2015-2020) 11 India11.1 India Targeted Biomarker Market Size (2015-2020)11.2 Targeted Biomarker Key Players in India (2019-2020)11.3 India Targeted Biomarker Market Size by Type (2015-2020)11.4 India Targeted Biomarker Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Targeted Biomarker Market Size (2015-2020)12.2 Targeted Biomarker Key Players in Central & South America (2019-2020)12.3 Central & South America Targeted Biomarker Market Size by Type (2015-2020)12.4 Central & South America Targeted Biomarker Market Size by Application (2015-2020) 13Key Players Profiles13.1 bioMerieux13.1.1 bioMerieux Company Details13.1.2 bioMerieux Business Overview and Its Total Revenue13.1.3 bioMerieux Targeted Biomarker Introduction13.1.4 bioMerieux Revenue in Targeted Biomarker Business (2015-2020))13.1.5 bioMerieux Recent Development13.2 IntegraGen13.2.1 IntegraGen Company Details13.2.2 IntegraGen Business Overview and Its Total Revenue13.2.3 IntegraGen Targeted Biomarker Introduction13.2.4 IntegraGen Revenue in Targeted Biomarker Business (2015-2020)13.2.5 IntegraGen Recent Development13.3 Myriad Genetics13.3.1 Myriad Genetics Company Details13.3.2 Myriad Genetics Business Overview and Its Total Revenue13.3.3 Myriad Genetics Targeted Biomarker Introduction13.3.4 Myriad Genetics Revenue in Targeted Biomarker Business (2015-2020)13.3.5 Myriad Genetics Recent Development13.4 Protagen13.4.1 Protagen Company Details13.4.2 Protagen Business Overview and Its Total Revenue13.4.3 Protagen Targeted Biomarker Introduction13.4.4 Protagen Revenue in Targeted Biomarker Business (2015-2020)13.4.5 Protagen Recent Development13.5 Qiagen13.5.1 Qiagen Company Details13.5.2 Qiagen Business Overview and Its Total Revenue13.5.3 Qiagen Targeted Biomarker Introduction13.5.4 Qiagen Revenue in Targeted Biomarker Business (2015-2020)13.5.5 Qiagen Recent Development13.6 PerkinElmer13.6.1 PerkinElmer Company Details13.6.2 PerkinElmer Business Overview and Its Total Revenue13.6.3 PerkinElmer Targeted Biomarker Introduction13.6.4 PerkinElmer Revenue in Targeted Biomarker Business (2015-2020)13.6.5 PerkinElmer Recent Development13.7 Merck Millipore13.7.1 Merck Millipore Company Details13.7.2 Merck Millipore Business Overview and Its Total Revenue13.7.3 Merck Millipore Targeted Biomarker Introduction13.7.4 Merck Millipore Revenue in Targeted Biomarker Business (2015-2020)13.7.5 Merck Millipore Recent Development13.8 Bio-Rad Laboratories13.8.1 Bio-Rad Laboratories Company Details13.8.2 Bio-Rad Laboratories Business Overview and Its Total Revenue13.8.3 Bio-Rad Laboratories Targeted Biomarker Introduction13.8.4 Bio-Rad Laboratories Revenue in Targeted Biomarker Business (2015-2020)13.8.5 Bio-Rad Laboratories Recent Development13.9 Enzo Biochem13.9.1 Enzo Biochem Company Details13.9.2 Enzo Biochem Business Overview and Its Total Revenue13.9.3 Enzo Biochem Targeted Biomarker Introduction13.9.4 Enzo Biochem Revenue in Targeted Biomarker Business (2015-2020)13.9.5 Enzo Biochem Recent Development13.10 EKF Diagnostics13.10.1 EKF Diagnostics Company Details13.10.2 EKF Diagnostics Business Overview and Its Total Revenue13.10.3 EKF Diagnostics Targeted Biomarker Introduction13.10.4 EKF Diagnostics Revenue in Targeted Biomarker Business (2015-2020)13.10.5 EKF Diagnostics Recent Development13.11 Meso Scale Diagnostics, LLC.10.11.1 Meso Scale Diagnostics, LLC. Company Details10.11.2 Meso Scale Diagnostics, LLC. Business Overview and Its Total Revenue10.11.3 Meso Scale Diagnostics, LLC. Targeted Biomarker Introduction10.11.4 Meso Scale Diagnostics, LLC. Revenue in Targeted Biomarker Business (2015-2020)10.11.5 Meso Scale Diagnostics, LLC. Recent Development 14Analysts Viewpoints/Conclusions 15Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See original here:
Targeted Biomarker Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Cole of Duty

Other Applications

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Personalized Medicine market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=254994&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=254994&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Originally posted here:
Personalized Medicine Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty

Abraham Maslow said in 1966, I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail. This mentality known as the Law of the Instrument indicates that people tend to rely on the tool with which they are most familiar.

In a healthcare setting, that can translate into only using traditionally trained medical professionals to handle every situation, but in reality, some issues require a collaborative approach that includes other skills and experience. This is particularly relevant when it comes to addressing social determinants of health (SDoH).

Social determinants of health can include many things: food, housing and transportation insecurities; lifestyles, locations and surroundings; social isolation; and other factors that prevent people from achieving and maintaining good health. Non-clinical influences like these can drive up to 80% of clinical outcomes, affecting an individuals ability to be healthy.

In other words, it takes more than the latest treatments to keep people healthy. Much work is being done to address social determinants at the public health level, but these factors must also be addressed at the patient level. The paradox about population health is that its all about individuals and using a collaborative approach can be the key to success.

Why the Collaborative Approach WorksStudies indicate that patients who perceive their providers as more empathetic tend to get better more quickly, and experience less severe symptoms. Yet providers sometimes lack the capacity to treat patients holistically, or the data and insights to understand why a patient isnt taking their medicine, even though insights into social barriers can guide how providers should interact with patients.

Educating a patient is helpful, but typically not effective at changing behavior, especially when social factors are at work. Additionally, people trained in the medical field are not also trained and resourced to deliver interventions involving social factors.

This is where an interdisciplinary team approach can help to improve population health by addressing social determinants at the individual level. The best approach to care involves a team that includes a range of medical professionals, social workers, behavioral health specialists and community health coaches, all working together to formulate and deliver a comprehensive support plan tailored to each patients priorities and needs.

Instead of telling patients what to do, local care teams can work with patients to understand their barriers, such as lack of transportation or housing insecurity, and tap local resources to reduce or remove them. By simply asking the right questions, community health coaches can get much more tactical and concrete about supporting the individual and tailoring treatment support plans.

Additionally, these coaches often live in the same community and understand the context of peoples lives, which improves communication and creates trust. In fact, Medicaid members who receive community-based services are less likely to be admitted to the ER or as an inpatient in a hospital. During one-on-one interactions, community health specialists are well-positioned to understand the social roadblocks to access care and adhering to treatment plans.

A collaborative team is ideally suited to assess the social and environmental factors impacting a persons health, identify barriers of care, and create a personalized support plan that may include services such as behavioral health support, patient advocacy, and remote monitoring technology to remove those barriers and improve care plan adherence.

The Four Components of SuccessA successful strategy to address social determinants of health comprises four components:

Analytics: In any population health intervention, the team needs to identify through stratification who is at the greatest risk, to properly titrate the resource intensiveness of an intervention. If you try to intervene equally with everyone, your efforts (and funds) will be spread too wide and too thinly.

Using analytics on the front end can ensure that the people with the highest risk are receiving more intensive treatments. Healthcare teams can look to existing data sets like consumer marketing data, which often is a treasure trove of information on factors that affect health such as transportation, housing issues and financial stress. For example, data can reveal if an individual lives alone, owns a car, or lives near public transportation all factors that impact a persons ability to follow through with their care plan. These insights can be integrated with data on medical risk and cost of care before the amalgamated data set is stratified.

A multidisciplinary support team: As stated, for social determinants to be addressed on an individual level requires an integrated team of both clinical and social support experts and community-based coaches are essential contributors.

The right toolbox from which to draw: There are existing toolboxes of interventions for housing, food insecurity and stress management, and the care team should recognize what needs to be addressed and draw from existing strategies to address healthcare at the social level. Interventions that mitigate the social stressors impacting an individual around the clock provide the greatest health benefits.

Respect for the individuals priorities: A population health team must have the flexibility to prioritize what the individual sees as the greatest issue. For example, a homeless individual might have a substance use disorder (SUD). Typically, people with SUD cannot get into housing until they are in recovery; however, if the individual is not ready to work on their recovery, but does see stable housing as a stepping stone toward recovery, that should be respected so work first on what theyre ready to work on.

A Better Approach to Addressing Population HealthWhile the use of multidisciplinary teams can involve significant changes to work practices and organizational arrangements, providing community-based resources is essential to addressing social barriers that affect health and wellness.

By understanding the social factors that can impact patient wellness, and employing a collaborative approach to individual care, payers, providers and patients will reap the benefits of more successful outcomes improving population health overall.

Photo: marchmeena29, Getty Images

See the original post here:
The paradox of population health: Focus on personalized support for the greatest impact - MedCity News

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its robust menu of ready-to-use Simoa kits to include tau phosphorylated at threonine 181 (p-tau181), a highly specific biomarker for the study of Alzheimers disease pathology, in cerebral spinal fluid (CSF), serum and plasma. A growing body of research, including work published recently in The Lancet Neurology, suggests that the biomarker could prove critical to predicting Alzheimers disease progression and differentiating the disease from other neurodegenerative disorders. Moreover, an ultra-sensitive, blood p-tau181 assay may hold the key to advancing preventative care for the disease in clinics and via homecare sampling through a simple, cost-effective blood-based screening that can deliver an early, objective diagnosis. These findings and details on how researchers can gain early access to Quanterix new commercial assay through the Simoa Accelerator Laboratory, will be discussed during an upcoming Powering Precision Health (PPH) Think Tank Webinar taking place at 10 a.m., EDT on June 3, 2020.

Biomarkers continue to play an invaluable role in understanding how neurological diseases manifest, progress and respond to treatment, said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix. Building on years of innovation and a proven track record for successfully commercializing ultra-sensitive assays that disrupt markets and drive innovative breakthroughs forward, our p-tau181 version 2 assay kit offers researchers unrivaled visibility and specificity into this revolutionary marker in serum and plasma. The exquisite sensitivity of Simoa uniquely positions us to deliver on the promise of p-tau181 to pave new pathways in Alzheimers disease exploration, just as our neurofilament light chain (Nf-L) assay has transformed research for other neurological diseases. In particular, the impact of a high-definition, blood-based Simoa assay that rivals traditional CSF or PET scans could be revolutionary, with material potential for home sampling to enable early detection and development and approval of drug therapies desperately needed to improve outcomes for the millions of people living with Alzheimers disease today. This biomarker advance fits perfectly in our vision to transform reactive sick care' into proactive asymptomatic precision healthcare.

While deaths associated with other pervasive diseases such as heart disease have declined between 2000 and 2018, Alzheimers disease-related deaths have increased by 146 percent, according to the Alzheimers Association. Importantly, there is no objective test to diagnose the disorder, leading many physicians to rely solely on subjective cognitive assessments. As a result, many patients are not diagnosed until late in the diseases progression, after symptoms of cognitive decline, such as memory loss, begin to present. Even then, the disease can often be misdiagnosed for another neurodegenerative condition, such as frontotemporal dementia (FTD).

For years, researchers have studied the utility of biomarkers for understanding, detecting and monitoring Alzheimers disease. These efforts have been accelerated in large part by the PPH network, which has grown into a global epicenter for biomarker-enabled innovations to not only detect and treat, but ultimately, prevent disease. Resulting studies demonstrate the vast utility of proteins such as total tau and Nf-L. Researchers, doctors and pharmaceutical companies are now harnessing these biomarkers to see the disease earlier, monitor its progression and inform clinical decision making more effectively, and assess the viability of experimental therapies. Quanterix ultra-sensitive immunoassay technology, Simoa, which empowers single- and multi-plex detection of key biomarkers with 1000 times greater sensitivity than competing enzyme-linked immunosorbent assay (ELISA) solutions, is the driving technology behind much of this research. Among the most notable is a 2019 Nature Medicine paper that used Simoa to see signs of Alzheimers disease 16 years before symptoms through the high-definition detection of Nf-L. The technology has powered hundreds of similarly peer-reviewed journals over the years that demonstrate the potential for blood-based detection of the disease with equal or greater sensitivity as compared to CSF or PET biomarkers. Collectively, these studies create an influential body of research that advances the preventative care paradigm envisioned by PPH at its inception by supporting the utility of a non-invasive and easily administered blood test to detect Alzheimers disease before symptoms.

Today, emerging research suggests that p-tau181 could hold even greater diagnostic promise for Alzheimers disease, as it has proven capable of differentiating the condition from other forms of dementia with greater specificity than total tau. Leaders in the field of neurodegenerative disease research, such as the authors of The Lancet Neurology paper Professors Henrik Zetterberg, MD, PhD, and Kaj Blennow, MD, PhD, of the University of Gothenburg, believe blood p-tau181 has the potential to revolutionize Alzheimers disease research and patient care in much the same way that serum-based Nf-L has for multiple sclerosis (MS).These concepts further progress PPHs mission and vision to harness biomarkers for true precision health, with myriad implications that include improving understanding of the condition, enabling earlier diagnosis and intervention, informing more accurate long-term care, identifying clinical trial candidates earlier in the disease cascade and, subsequently, accelerating promising new therapies to market.

The latest installment of the PPH Think Tank series of webinars, entitled Novel p-tau181 Blood Immunoassay and the Future of Alzheimers Disease Research, will explore the vast opportunities associated with p-tau181 to revolutionize the way we approach disease and administer care. Specifically, the discussion will detail how an innovative immunoassay to measure p-tau181 in blood could accelerate efforts to establish a clinically relevant routine Alzheimers disease diagnostic test, and the potential high-definition detection via small volume blood samples creates for homecare precision health. Hrusovsky, together with Professors Zetterberg and Blennow, will break down the findings from the recent paper in The Lancet Neurology and examine how Simoa is powering exploration into uncharted territory as it pertains to Alzheimers disease detection, monitoring, treatment and prevention.

Were on the cusp of what could be an incredible new era for Alzheimers patients and those with a genetic predisposition to the disease, said Zetterberg. The ability to see dementia asymptomatically and moreover conclusively distinguish it as Alzheimers disease-induced could forever change the face of this condition. P-tau181 shows immense promise in this regard, which is augmented considerably when harnessed by a leader in detection like Quanterix.

Early findings from our work with p-tau181 are very encouraging, said Blennow. The biomarker is proving to be an exceptional new tool in our arsenal against Alzheimers disease. While CSF p-tau181 has been recognized as a highly valuable biomarker in Alzheimers disease pathology, the greater clinical benefit will come from our ability to effectively harness the marker in blood. The unprecedented specificity of p-tau181 paired with a highly sensitive technology like Simoa promises to broaden our knowledge of this devastating disease considerably, with monumental implications for patients and caregivers.

To register for the webinar, click here.

To learn more about how you can take advantage of our early access program for p-tau181 through the Accelerator Lab or pre-order your commercial kits, visit https://www.quanterix.com.

For more about Quanterix Simoa technology, visit https://www.quanterix.com/Simoa-bead-technology.

About Quanterix

Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health. The companys digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

About Powering Precision Health

Powering Precision Health is the world's first independent, non-profit organization dedicated to bringing the world's leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Founded by Kevin Hrusovsky, a widely acclaimed thought leader and visionary in life sciences and personalized medicine, Powering Precision Health is a movement that represents the intersection of new technological capabilities with the latest medical research. Its rooted in the science of precision medicine, which shows personalized treatments to be an increasingly more effective way to maximize drug efficacy and minimize toxicity. In addition to the impact environmental and lifestyle factors can have on minimizing disease triggers, precision health marks an evolution in the way we approach disease and aims to inspire a full healthcare transformation, from philosophy to approach to outcome. In an industry often plagued by skepticism and marred by false promises, PPH puts science first and brings together stakeholders that span from fundamental research to clinical practice, investors, policy makers, patient advocacy groups, and anyone who embraces the vision of Powering Precision Health. Featuring a distinguished keynote lineup of dignitaries, the Summit unveils groundbreaking approaches to prevention, early diagnosis, and next-generation treatments. Powering Precision Health is supported thanks to the generous contributions of sponsors from a wide range of companies and organizations committed to advancing precision health.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

See more here:
Quanterix Expands Menu of Ultra-Sensitive Neurology Assays with Simoa P-Tau181 V2 Kit for Improved Detection and Study of Alzheimer's Disease -...

New Jersey, United States, The Personalized Medicine Market report examines the market situation and prospects and represents the size of the Personalized Medicine market (value and volume) and the share by company, type, application and region. The general trends and opportunities of Personalized Medicine are also taken into account when examining the Personalized Medicine industry. Personalized Medicine The market report focuses on the following section: Analysis of the Personalized Medicine industry by transfer into different segments; the main types of products that fall within the scope of the report.

This Personalized Medicine market report is a complete analysis of the Personalized Medicine market based on an in-depth primary and secondary analysis. The scope of the Personalized Medicine market report includes global and regional sales, product consumption in terms of volume and value. The Personalized Medicine market report contains an estimate of revenue, CAGR and total revenue. The knowledge gathered in world trade Personalized Medicine is presented in figures, tables, pie charts and graphics.

Get | Research Sample Copy By Using Corporate Mail ID @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=COD&utm_medium=007

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Drivers and Restrains

The research report included analysis of various factors that increase market growth. These are trends, restrictions and drivers that change the market positively or negatively. This section also contains information on various segments and applications that may affect the market in the future. Detailed information is based on current trends and historical milestones. This section also includes an analysis of sales volume on the Personalized Medicine market and for each type from 2015 to 2026. This section mentions sales volume by region from 2015 to 2026. The price analysis is included in the report Type of year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020 and total price from 2015 to 2026.

An in-depth assessment of the restrictions contained in the report describes the contrast to the drivers and leaves room for strategic planning. The factors that overshadow the growth of the market are essential as they can be understood to design different phrases to take advantage of the lucrative opportunities that the growing Personalized Medicine market offers. In addition, information on the opinions of market experts was used to better understand the market.

Global Personalized Medicine Market: Segment Analysis

The research report contains certain segments such as application and product type. Each type provides revenue information for the 2015-2026 forecast period. The application segment also provides volume revenue and revenue for the 2015-2026 forecast period. Understanding the segments identifies the importance of the various factors that support Personalized Medicine market growth.

Global Personalized Medicine Market: Regional Analysis

The research report includes a detailed study of the regions of North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Personalized Medicine report was compiled after various factors determining regional growth, such as the economic, environmental, social, technological and political status of the region concerned, were observed and examined. Analysts examined sales, sales, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2015 to 2026. These analyzes help the reader understand the potential value of investments in a particular region.

Global Personalized Medicine Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. It helps the reader understand the strategies and collaborations that players focus on to fight competition in the market. The full report provides a significant microscopic overview of the Personalized Medicine market. Readers can identify manufacturers footprints by knowing manufacturers global earnings, manufacturers world market prices, and manufacturers sales for the 2015-2019 forecast period.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=COD&utm_medium=007

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

See the article here:
Personalized Medicine Market Growth Analysis by Size, Top Companies, Supply Demand, Trends, Demand, Overview and Forecast to 2026 - Cole of Duty

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ability of Myriads riskScore test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions.

We are excited to further demonstrate Myriads commitment to providing the best possible risk assessment tools to patients through innovation, said Nicole Lambert, president of Myriad Oncology, Myriad Womens Health and Myriad International. The validation data we are presenting at ASCO this year will support a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool.

Summaries of the studies are below. Follow Myriad on Twitter via @myriadgenetics and keep up to date with ASCO meeting news and updates by using the #ASCO20 hashtag.

riskScore Presentations at 2020 ASCO:

Title:Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) modelPresenter:Mark E. Robson, MD, Memorial Sloan Kettering Cancer CenterLocation:https://meetinglibrary.asco.org/record/187438/abstract

In this study, 358,471 women with hereditary cancer risk who were tested with a multigene panel were assessed to find 4,331 women who were carriers of deleterious CHEK2 mutations. These patients were used to develop a mathematical model to assess risk status using family history information and Myriads riskScore test. This model was then validated in an independent cohort of 459 women. In CHEK2 pathogenic variant carriers, a significant correlation was detected of CHEK2 status with family history (FH) (p=4.1 10-17) and of polygenic risk scores with FH among CHEK2 carriers (p=1.7 10-5). Among the patients in the validation cohort, 24.0% of CHEK2 carriers were categorized as low risk (<20%), and 62.6% were categorized as moderate risk (20-50%). For 13.4% of CHEK2 carriers, risk estimation incorporating PRS and TC generated BC risks of greater than 50%, consistent with genes recognized as highly penetrant.

To view Graph 1: Precision Breast Cancer Risk Categorization of CHEK2 Carriers,please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/1a4a8828-8282-47df-9e4d-b82f11604b2b

Title:Performance of the IBIS/Tyrer-Cuzick (TC) Model by Race/Ethnicity in the Womens Health InitiativePresenter:Allison W. Kurian, M.D., M.Sc, Stanford UniversityLocation:https://meetinglibrary.asco.org/record/185965/abstract

In this study, 91,893 women of differing racial identities with no personal history of breast cancer were followed for a median of 18.9 years to assess incidence of breast cancer. 6,836 new cases of breast cancer were diagnosed among the women. The Tyrer-Cuzick model was used to assess risk of breast cancer and then actual cases of breast cancer were compared to expected cases based upon the Tyrer-Cuzick risk assessment. The study found that the Tyrer-Cuzick model was an accurate predictor of breast cancer risk among various ethnicities except for Hispanic women where it overestimated breast cancer risk (ratio of observed versus expected cases overall was 0.95).

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

Story continues

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read this article:
Myriad Presents New Data at ASCO Validating the Ability of riskScore to Provide Personalized Breast Cancer Risk Information to Patients - Yahoo...

3DHEALS 2020

SAN FRANCISCO (PRWEB) May 29, 2020

3DHEALS, LLC is pleased to announce its global virtual summit 3DHEALS 2020, June 5th- June 6th, focusing on healthcare innovations using 3D printing, bioprinting, and related technologies. The event expects 500+ attendees from 20+ countries, and 20 early-stage startups to participate in Pitch3D, a fast-paced pitch event to institutional investors. 3DHEALS 2020 addresses the need for a global cross-disciplinary forum. It will feature more than 70 world-class experts from more than 60 organizations and companies to showcase technological developments, share insights, tackle challenges, and present opportunities for future collaborations. The content-rich two-day multi-track virtual summit allows the attendees to learn practical knowledge from world-class experts, including hands-on application-focused workshops. The organizers have conducted more than 29 speaker interviews, which can also be downloaded as podcasts.

The virtual summit is not just two days of webinars, but a simulated virtual networking experience, where speakers, exhibitors, and attendees can engage through the conference's dedicated mobile app, before, during, and after the meeting. The fee for the conference is 100 USD.

The two-day virtual event offers nineteen sessions. While there is no dedicated COVID-19 panel, many presentations address how 3D printing and bioprinting communities respond to the pandemic.

Highlighted presentations and panels include the following:

In the first keynote presentation, Sam Onukuri, Head and Senior Fellow at Johnson & Johnson 3D Printing, will explain how the world's largest healthcare company is leveraging 3D printing technology to transform the design, manufacturing and delivery ecosystem across Johnson & Johnson's medical device, consumer and pharmaceutical businesses.

In the second keynote presentation, Dr. Alan Dang, an orthopedic spine surgeon and co-founder of PrinterPezz, will share the "behind-the-scenes secrets" of how PrinterPrezz democratizes medical device innovation and helps its customers go from concept to production.

The biofabrication and bioprinting panels collect some of the brightest minds in the world of tissue engineering and biofabrication, tackling 3D printing nearly every organ system from brain tissue, vasculatures, to heart valve. Many speakers are well-known scientists, including professors Stephanie Willerth, Adam Feinberg, Jordan Miller, who are also co-founders behind some of the newest startups in the bioprinting space. More established companies critical to tissue engineering and cell therapy will also join the conversation, including Melanie Mathieu from Prellis Biologics, Jon Rawley from Roosterbio, John O'Neil from Xylyx, Taciana Pereira from Allevi, and Kevin Caldwell from Ossium Health, and Qrquidea Garcia ("Orchid") from JNJ.

A related panel focusing on 3D printing on the International Space Station also deserves much attention from speakers from Techshot, ISS/CASIS, and Allevi (Ricky Solorzano).

The legal and regulatory panel will include the most comprehensive list of legal and regulatory concerns, focusing on healthcare 3D printing applications. The topics include intellectual property/patent issues(Roger Kuan, Haynes and Boone LLP), product liability, FDA pathways, manufacturing standards, and more. Steven Bauer, from FDA CBER, will address concerns related to cell therapy and stem cells.

The early morning Global Perspective sessions are reserved for international speakers to share their unique experiences, needs, and hopes. Both America Makes director John Wilczynski and NAMIC director Dr. Chaw Sing Ho, along with experts from Turkey, India, and Taiwan, will share how 3D printing and bioprinting innovations can thrive in both local and global healthcare environs. The audience will also learn about how different countries are implementing the concept of 3D printing for Point of Care, with experts from UCSF, Stanford, Germany (Kumovis), India (Anatomiz3D), Korea (MEDICALIP), and developing countries. More than ten 3DHEALS community managers will also present city-based healthcare 3D printing innovation ecosystems and share their progress.

As one of the largest sectors in FDA cleared devices, metal and orthopedic 3D printing will permeate throughout the entire conference, from keynotes to dedicated panels focusing on materials, designs (nTopology, ANSYS, MEDICALIP), and end-user applications head to toe (Printerprezz).

As a fast-growing sector, the dental 3D printing panel will feature an unprecedented group of speakers from a combination of academia (University of Michigan, USC, UOP) and industry (Boneeasy, Origin) focusing on critical issues facing the industry both short and long term.

The material science panel will feature speakers from Henkel, Evonik, Origin, and 3Degrees for an in-depth discussion on what roles material manufacturers should play in 3D printed medical devices, investment opportunities, and the latest trends.

The investor panel will feature VCs in the medtech and life science space, including NEA, Intuitive Surgical, Evonik, and more.

The entrepreneur fireside chat session will invite CEOs of Aspect Biosystems and Fluidform to share their perspectives based on their startup journeys.

Go here to see the original:
3DHEALS 2020: Join The Frontier Of Healthcare 3D Printing - PR Web

DUBLIN, May 28, 2020 /PRNewswire/ -- The "Nuclear Medicine Imaging Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis and the looming economic recession, the Nuclear Medicine Imaging Equipment market worldwide will grow by a projected US$525 Million, during the analysis period, driven by a revised CAGR of 2.9%. Hybrid Positron Emission Tomography (PET) Systems, one of the segments analyzed and sized in this study, is forecast to grow at over 3.5% and reach a market size of US$1.3 Billion by the end of the analysis period. The Hybrid Positron Emission Tomography (PET) Systems market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 1.8% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$12.2 Million to the region's size over the next 7 to 8 years. In addition, over US$13 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Hybrid Positron Emission Tomography (PET) Systems segment will reach a market size of US$62.5 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Nuclear Medicine Imaging Equipment market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 5.9% over the next couple of years and add approximately US$176.5 Million in terms of addressable market opportunity.

Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Nuclear Medicine Imaging Equipment market landscape.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/e8egzt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
World Nuclear Medicine Imaging Equipment Market Analysis, Featuring Digirad Corporation, GE Healthcare, Mediso Medical Imaging Systems and Philips...

Precision Medicine Market2019 Industry Research Report provides important statistics, analytical and comparative data to give a complete understanding of the market Share, Size, Growth, Rising Trends and Cost Structure analysis.

Get Sample Copy of this Report at https://www.orianresearch.com/request-sample/559884

This report offers in-depth information obtained through extensive primary and secondary research methods. The information has been further assessed using various effective analytical tools.

The report puts special emphasis on the most important details of the Global Precision Medicine Market Report 2019 market, filtered out with the help of industry-best analytical methods

Regionally, North America, Latin America, Europe, Asia Pacific, And The Middle East & Africa constitute the key market segments.

Top Key Players Analyzed in Global Precision Medicine Marketare

Complete report on Precision Medicine Industry spread across 122 pages, profiling 10 companies and supported with tables and figures. For more details Enquire @https://www.orianresearch.com/enquiry-before-buying/559884

Key Benefit Of This Report:

Target Audience:

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/559884

Major Points Covered in Table of Contents:

7 Global Precision Medicine Market By Product Type

8 Global Precision Medicine Market By Applications

9 Global Precision Medicine Market By Region

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About UsOrian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

The rest is here:
COVID-19 Impact on Global Precision Medicine Industry 2020: Market Trends, Size, Applications, SWOT Analysis by Top Key Players and Forecast Report to...

The Global Genetic Testing Market is expected to register substantial growth in the near future due to rise in incidence of genetic disorders & cancer and growth in awareness and acceptance of personalized medicines.

Genetic testing is also known as DNA testing. Genetic testing is the study of gene present in cells and tissues. This study is further applied in the field of biology and medicine to better understand genetic disorders such as cancer, sickle cell anemia, cystic fibrosis, Down syndrome, and others. The scope of the report discusses the use of gene tests for the development of personalized medicine, targeted cancer treatment, and other genetic diseases.

In addition, advancements in genetic testing techniques and increasing application of genetic testing in oncology are expected to boost the market growth during the forecast period.Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. The Geographical Segmentation includes study of global regions such as North America, Latin America, Asia-Pacific, Africa, and Europe. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

Get Sample Copy of this [emailprotected] https://www.marketresearchinc.com/request-sample.php?id=16612

Highlighted key points of this market research report:

Profiling Key Players:

Get Maximum Discount Now @ https://www.marketresearchinc.com/ask-for-discount.php?id=16612

Genetic Testing Key Market Segments:

By Product Type:

By Technology Type:

By Application Type:

Different top-level key players are also enlisted in order to obtain in-depth knowledge and informative data of companies. Some of the key players are also profiled in this research report, which includes Genetic Testing Market. Different industry analysis tools such as SWOT and Porters five-technique are further used while analyzing the global Genetic Testing Market.

For More Inquiry Detailed TOC Of Research Report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=16612

The report also draws attention to recent advancements in technologies and certain methodologies which further help to boost the outcome of the businesses. Furthermore, it also offers a comprehensive data of cost structure such as the cost of manpower, tools, technologies, and cost of raw material. The report is an expansive source of analytical information of different business verticals such as type, size, applications, and end-users.

Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market.

Table of Content:

Chapter 1:Genetic Testing Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Genetic Testing Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Genetic Testing Market Effect Factors Analysis

Chapter 12: GlobalGenetic Testing Market Forecast to 2025

Finally, all aspects of the Genetic Testing Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact Us:Author KevinUS Address: 51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225 1818Email: [emailprotected]

Read the original:
Rapid Growth on Genetic Testing Market with COVID-19 Impact Analysis, Top Key Companies like Abbott Laboratories Bio-Rad Laboratories Inc.,...

Pancreatic cancer is a deadly malignancy with few treatment models. Monolayer cell culture has failed to predict patient drug responses in the past. In response to this, a patient-derived organoid (PDO) methodology has been developed that enables the generation of models, from both surgically resected material and biopsies, with a success rate of 75-80%. These cultures enable the molecular dissection of treatment responses and resistance.

Here, Dannielle Engle and Christian Oberdanner will discuss the use of the Tecan SparkCyto to evaluate drug responses in PDO models. In short, PDO models were plated in a 384-well format, allowed to reform, and treated with compounds. The dose-responses of PDO models were compared to several agents using both CellTiter-Glo (Promega) to measure ATP levels, as well as the automated confluence measurement. This methodology provided the same endpoint analyses previously relied upon, plus the dynamic evaluation of changes to cell morphology and confluence. Confluence measurements were found to be comparable to ATP levels. Given the diversity observed amongst pancreatic cancer patients and the PDO models, dynamic measurements provide additional flexibility and information for precision medicine approaches.

Key learning objectives:

Who should attend:

Read the original:
Predicting drug responses using pancreatic cancer organoids and multimodal plate imaging on SelectScience - SelectScience

FORT WORTH, Texas, May 27, 2020 /PRNewswire/ --CQuentia joinsthe American Heart Association Center for Health Technology and Innovation (the Center) Innovators' Network, which is focused on building and fostering health technologies and relationships in pursuit of innovative and scalable solutions across the healthcare market.

The Center's Innovators' Network helps its members align and integrate their technology with the Association's science-based health management plans, called CarePlans, to encourage development and adoption of digital healthcare solutions.

CQuentia is a next-generation sequencing FDA CLIA laboratory and data service that brings a comprehensive precision medicine platform to the Association's Innovators' Network. When integrated with the American Heart Association CarePlans, CQuentia combines advanced genomics including pharmacogenomics testing and molecular genetic pathology testing to deliver reliable, accurate and actionable genetic and molecular information in concert with leading science and technology. Providers, hospitals and payers are now actively seeking the means to customize care of their patients based on this type of individualized data.

"What separates CQuentia from other genetic testing laboratories is our platform-agnostic approach to deliver solutions and our ability to create client specific reports and alerts that are personalized to target disease state and comorbidities," said Alan Meeker, CQuentia CEO.

This endeavor aims to couple the knowledge gained from CQuentia's genomic testing to drive better personal adherence and control using the Association's CarePlans and health content.

"It's incredibly encouraging to see CQuentia leveraging best-in-class science from the American Heart Association with the aim of improving health education and health engagement," said Patrick Wayte, senior vice president of the American Heart Association Center for Health Technology and Innovation.

About CQuentia CQuentia is a privately-held molecular testing and laboratory company positioned to provide doctors, governments and employers with rapid, reliable results; enabling them to make informed clinical and population health decisions on how to provide the world with the most appropriate restorative care and infection prevention guidance.

For more information, please visit http://www.cquentia.com/covidtesting

SOURCE CQuentia

http://www.cquentia.com/

Read more:
CQuentia joins American Heart Association's Center for Health Technology & Innovation Innovators' Network with a focus on Precision Medicine -...

Biobanks are essentially repositories for storing biological substances derived from humans, which may include organs, bio-specimens, plasma, saliva, and blood. With a vast rise in the number of organ replacement surgeries globally and significant advancements made in the fields of transfusion and replacement technologies, the role of the biobanks market has become more concrete in the healthcare sector in recent years.

The global biobanks market has witnessed expansion at a significant pace in the recent years owing to the vast rise in prevalence of a number of chronic diseases and the increased demand for personal medicine. The massive rise in incidence rate of conditions such as diabetes, cancer, neurovascular diseases, cardiovascular diseases, and respiratory diseases has compelled government bodies to take stronger actions in terms of investments in biobanks and increasing awareness about them. The global market for biobanks works in coherence with these efforts by adding pace to the process of drug discovery and the treatment of chronic diseases that are caused by activities such as smoking, consumption of alcohol, obesity, and unhealthy lifestyles.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321

Heavy investment by a proactive government has boosted the North America biobanks market to the leading position in the global biobanks market, followed closely by Europe. Both regions are home to several bioscience companies and host a large number of drug discovery and research activities. Asia Pacific still remains the region with the most promising growth potential as the region shown high promise owing to an increase in investments from both government and non-government organizations, along with a large and increasingly affluent population base that is gaining awareness about the market.

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=2321&ltype=S

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2321

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Continue reading here:
Biobanks Market - Rising need for replacement organs and the steady advancement in the replacement drive growth of market - BioSpace

This special report sponsored by Dell Technologies, takes a deep dive into HPC and AI for life sciences in the era of genomics. 2020 will be remembered for the outbreak of the Novel Coronavirus or COVID-19. While infection rates are growing exponentially, the race is on to find a treatment, vaccine, or cure. Governments and private organizations are teaming together to understand the basic biology of the virus, its genetic code, to find what can stop it.

Significant amounts of computing power are aimed at this problem, including using the most powerful high performance computing (HPC) systems in the world today. Finding a cure or eliminating COVID-19 will not only benefit the worldwide population, but will also be the foundation for tackling the next pandemic, which some scientists say will happen in the not too distant future.

This technology guide, insideHPC Special Report: HPC and AI for the Era of Genomics, highlights a lineup of Ready Solutions created by Dell Technologies which are highly optimized and tuned hardware and software stacks for a variety of industries. The Ready Solutions for HPC Life Sciences have been designed to speed time to production, improve performance with purpose-built solutions, and scale easier with modular building blocks for capacity and performance.

Introduction

2020 will be remembered for the outbreak of the Novel Coronavirus or COVID-19. While infection rates are growing exponentially, the race is on to find a treatment, vaccine, or cure. Governments and private organizations are teaming together to understand the basic biology of the virus, its genetic code, to find what can stop it. Significant amounts of computing power are aimed at this problem, including using the most powerful high performance computing (HPC) systems in the world today.[1] Finding a cure or eliminating COVID-19 will not only benefit the worldwide population, but will also be the foundation for tackling the next pandemic, which some scientists say will happen in the not too distant future.[2]

Artificial Intelligence (AI)

Slav Petrovski, Head of Genome Analytics and Informatics at AstraZenecas Centre for Genomics Research (CGR) explains that there is a wide range of uses for AI within this field. He says that the approximately three billion base pairs that make up the human genome can be analyzed through AI to find genetic variations. The next step is to determine the level of confidence to be placed in the differing data to decide if it represents a biological genetic variant.

AI is being combined with traditional HPC simulations to predict more accurate results. Based on previous completed computations, an algorithm is able to determine what the next input or result could be. For example, if protein A shows a possible affinity to kill the Coronavirus, then does protein B (or others) have a better chance or could be more effective?

There are a number AI uses within genomics research that can identify and facilitate drug target interaction. By combining analytical and automated processes with the ongoing study of genomics, a more complete understanding of this field will progress. AI can lead to greater insights into the patterns and anomalies in the data, where humans may not see the correlations at first. By using machine and deep learning techniques, new and more effective medicines can get to patients faster and will be better targeted to fight diseases.

Produvia, a research company, has identified five areas where AI will benefit genomic research moving forward:

Precision Medicine

While AI can benefit genomic research, the end goal is to create treatments that specifically attack the genetic code of the infection or disease, and to create treatments that are tailored to an individuals genetic makeup. To do this requires significant data, computing power, and collaborations that combine expertise from many disciplines.

With a combination of faster and more accurate genomic sequencing with faster computer systems and new algorithms, the movement of discovering what medicine will work best on individual pathogens and patients has moved from research institutions to bedside doctors. Physicians and other healthcare providers now have better, faster and more accurate tools and data to determine optimal treatment plans based on more data. This is especially true for pediatric cancer patients.

Personalized or precision medicine holds the key to innovative approaches to manage diseases on an individual level. Various decisions regarding the management of healthcare to each pathogen and/or individual is customized, based on the knowledge of the genetic or cellular information. Diagnosis of diseases, and the resulting treatments can be tailored for each person. However, a number of challenges exist as this scientific field moves forward, such as regulatory oversight, intellectual property rights and patient privacy.

Worldwide, many countries are dedicating resources and efforts to learn more about genomics and how to apply this knowledge to personalizing medicine. Figure 1 shows the worldwide effort to bring precision medicine to those in need. Figure 2 shows how the cost of decoding a human genome has come down, even faster than Moores Law.

Over the next few weeks we will explore these topics surrounding HPC and AI for life sciences in the era of genomics:

Download the complete insideHPC Special Report: HPC and AI for the Era of Genomics, courtesy of Dell Technologies.

[1] COVID-19 HPC Consortium

[2] Scientists in race to protect humanity from future pandemics

See more here:
insideHPC Special Report: HPC and AI for the Era of Genomics - insideHPC

NEW YORK, NY, UNITED STATES - May 27, 2020 - Recently founded, the New York-based company AI & Medicine is an expert in the field of AI-Powered drug discovery, personalized healthcare and various medical applications. Having launched a unique AI-aided drug discovery platform last month, this company grows quickly with concerted support from many talented researchers and scientists. It offers drug R & D solutions from the perspective of AI for medical institutions and pharmaceutical enterprises worldwide.

AI is transforming the practice of medicine. Owing to its ability to identify meaningful relationships in raw data, AI can be used in multiple medical scenarios. For example, it helps doctors diagnose patients more accurately, make predictions about patients future health, and even recommend better treatments. It is quite fair to say that AI can be applied in nearly every field of medicine.

AI & Medicine can help apply machine learning to solve the following four concrete problems:

Drug Research and Development

Through big data analysis and other technical means, the AI-powered drug discovery platform offered by AI & Medicine can quickly and accurately mine data and select the appropriate lead compounds. Especially in contrast with traditional methods, AI can help save a great deal of time, cost, and energy in a range of steps regarding drug discovery, including drug target discovery, candidate drug discovery, prediction of drug crystal form, ADMET prediction, design and optimization of clinical trials, pharmacovigilance, etc.

Medical Translation

The company's AI technology has accumulated a lot in big data, natural semantic analysis, machine learning and deep neural network. A team of scientist with well-equipped knowledge in medical field is capable of optimizing the medical translation system, offering multilingual translation and at the same time ensure the standard and preciseness of medical translation.

Medical Imaging

AI technology is applied in medical imaging area through imaging analysis and surgical simulation.

Main AI methods include image segmentation, feature extraction, quantitative analysis, comparative analysis, etc. AI is increasingly helping to reveal hidden insights into clinical decision-making, connect patients with resources for self-management, and extract meaning from previously inaccessible, unstructured data assets.

Medical Therapy and Research

The company's Intelligent Inquiry and Guidance platform uses the medical AI engine to accurately identify and match the needs of both doctors and patients. Advanced analytics and machine learning techniques are being used concurrently to help uncover critical insights and best practices from the billions of data elements associated with robotic-assisted surgery. Moreover, AI is also helpful in electronic medical record establishment, literature reading and information extraction.

To learn more information about AI & Medicine's capability in AI-powered drug discovery and medical application, please visit:https://aimed.protheragen.com/solutions.html.

About AI & Medicine

Missioned to helping fulfill the specific drug R&D requirements in the industry, AI & Medicine successfully develops an AI-powered drug discovery platform for medical institutions and pharmaceutical enterprises across the globe, offering a broad and integrated portfolio of medical and scientific solutions in areas like drug R&D, medical translation, medical imaging, medical therapy and research system, and more.

Here is the original post:
AI & Medicine An Expert in AI-aided Drug Discovery and Medical Applications - Bio-IT World

Dublin, May 27, 2020 (GLOBE NEWSWIRE) -- The "Global Next-generation Sequencing Market By Product (Consumables, Platforms and Services), By Technology (Sequencing by Synthesis, Pyrosequencing, and Other Technologies), By End User, By Application, By Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Sequencing Market is projected to grow at a CAGR of close to 20% to reach USD24 billion during the forecast period.

Enhancing regulatory framework for next-generation sequencing based tests for diagnostics is the key factor for the growth of the Global Next-Generation Sequencing Market during the forecast period. Moreover, advancements in next-generation sequencing coupled with reduction in the price of NGS platforms are some other major factors that are anticipated to bolster the growth of the Global Next-Generation Sequencing Market over the coming years. However, some of the factors that might act as major impediments to the growth of the Global Next-Generation Sequencing Market includes concerns pertaining to the standards of NGS based diagnostics.

The Global Next-Generation Sequencing Market is segmented based on product, technology, end-user, application, region and company. Based on technology, the market can be segmented into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing and other technologies. Among them, the sequencing by synthesis (SBS) segment dominated the market until 2019 and is projected to grow with a healthy CAGR over the forecast period due to development of new and advanced NGS platforms along with the rising demand for Illumina's systems as it uses the SBS technology.

Major players operating in the Global Next-Generation Sequencing Market include Illumina, Inc., Thermo Fisher Scientific, Inc, BGI Group, Agilent Technologies, Inc., Qiagen N.V., Hoffmann-La Roche AG, 10x Genomics, Oxford Nanopore Technologies, Takara Bio and others.

Objective of the Study:

The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of service providers across the globe. Subsequently, they conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the service providers which could not be identified due to the limitations of secondary research. The author analyzed new services, distribution channels and presence of all major players across the globe.

The author calculated the market size of the Global Next-Generation Sequencing Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. Researchers sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Next-generation Sequencing (NGS) Market Outlook5.1. Market End User & Forecast5.1.1. By Value5.2. Market Share & Forecast5.2.1. By Product (Consumables, Platforms and Services)5.2.1.1. By Consumables (Sample preparation consumables and Other Consumables)5.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)5.2.1.3. By Services (Sequencing Services and Data management services)5.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing and Other Technologies)5.2.3. By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)5.2.4. By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Other Applications)5.2.5. By Region5.2.6. By Company (2019)5.2.6.1. By NGS Platform

6. North America Next-generation Sequencing (NGS) Market Outlook6.1. Market End User & Forecast6.2. Market Share & Forecast6.3. North America: Country Analysis

7. Europe Next-generation Sequencing (NGS) Market Outlook7.1. Market End User & Forecast7.2. Market Share & Forecast7.3. Europe: Country Analysis

8. Asia-Pacific Next-generation Sequencing (NGS) Market Outlook8.1. Market End User & Forecast8.2. Market Share & Forecast8.3. Asia-Pacific: Country Analysis

9. Middle East and Africa Next-generation Sequencing (NGS) Market Outlook9.1. Market End User & Forecast9.2. Market Share & Forecast9.3. MEA: Country Analysis

10. South America Next-generation Sequencing (NGS) Market Outlook10.1. Market End User & Forecast10.2. Market Share & Forecast10.3. South America: Country Analysis

11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape (NGS Platform Providers)13.1. Competition Outlook13.2. Company Profiles13.2.1. Illumina, Inc.13.2.2. Thermo Fisher Scientific, Inc13.2.3. BGI Group13.2.4. Perkinelmer13.2.5. Agilent Technologies, Inc.13.2.6. Qiagen N.V.13.2.7. F. Hoffmann-La Roche AG13.2.8. 10x Genomics13.2.9. Oxford Nanopore Technologies13.2.10. Takara Bio

14. Strategic Recommendations

15. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/2rcwyi

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Insights on the Worldwide Next-generation Sequencing Industry to 2025 - Featuring Illumina, BGI Group & Perkinelmer Among Others - GlobeNewswire

A month following surgery for thyroid cancer, a Hartford Hospital patients tumor grew to 10 inches. The case was presented to the hospitals tumor board, which involved 30 doctors from different specialties.

The gene mutation found to be controlling the patients tumor growth was already well-established as a driver of melanoma, the deadliest form of skin cancer, says Dr. Sope Olugbile, medical oncologist at Hartford HealthCare.Chemotherapy wouldnt work fast enough against the aggressive tumor. Tumor board members recommended a targeted therapy already treating patients with melanoma. Without that genetic information, we wouldnt have been able to come up with that therapy, he says. The treatment saved the patients life, so far. Our goal is to use more of the genetic information to drive the treatment of cancer patients.

This type of personalized care, known as precision medicine and its subset, genomic medicine, has been offered for years at world-renowned cancer-treatment hospitals such as Memorial Sloan Kettering Cancer Center in New York, Dana-Farber Cancer Institute in Boston and University of Texas MD Anderson Cancer Center in Houston. Its now the standard of care in Connecticuts Hartford HealthCare Cancer Institute, UConn Health Center in Farmington, Connecticut Childrens Medical Center in Hartford and Smilow Cancer Center at Yale New Haven Health.Cancer therapy has become precision therapy, says Dr. Roy Herbst, professor of medicinal oncology and pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital.

Dr. Roy Herbst, of Yale Cancer Center and Smilow Cancer Hospital, says that precision care is often used in cancer treatment these days.

While its most commonly used with cancer patients, precision medicine is also making inroads into other areas of health care including the treatment of some cardiac patients. Its also being studied and used on a limited basis to treat those with rare diseases. In the U.S., newborns are screened with a blood test for hearing loss and heart defects. If detected and treated early, this can prevent death and disability in some cases. For some doctors and researchers, precision medicine holds the promise of effective targeted diseases and chronic conditions, and, even more revolutionary, the chance to prevent illness before it arises. The race is on to gather as much data as possible in order to increase understanding of the connection between genes and overall health; here in Connecticut, Yales Center for Genetic Health last fall launched its Generations project to collect DNA from 100,000 volunteers (see sidebar below).

Precision medicine involves the study of human genes, called the genome. The human genome contains 23 pairs of chromosomes within all human cells, and each chromosome contains hundreds to thousands of genes. Using high-level computing and mathematics, genomics researchers analyze massive amounts of DNA-sequence data to find variations or mutations that affect health, disease or response to drugs, according to an online description by The Jackson Laboratory for Genomic Medicine in Farmington.

Researchers can sequence an entire tumor to look for markers or abnormalities that can be treated with a targeted medication that attacks that mutation, unlike traditional chemotherapy that kills healthy cells along with cancer cells, says Herbst, also associate director for translational science at the Yale School of Medicine.

These days, when Yales precision medicine tumor board meets weekly, they dont focus on where the tumor began, he says. They look at what errors occurred in the DNA of the tumor, because once they know whats driving the tumor, they can treat it.For example, lung cancer is the most common cancer in the world. When a nonsmoker gets lung cancer, doctors sequence the tumors DNA to see if it contains one of eight genes known to mutate.

Each cancer cell has about 18,000 to 20,000 genes, and there are some cancers where just one of those genes is directing the growth of the cancer, Olugbile says. We call that the driver gene. The other 17,999 are just following the lead of that driver gene, he says. That means if we tag just that one gene with the medication then we can actually shut down the growth of the entire cancer.

Traditional chemotherapy can only be given for 4-6 months because of the side effects, while targeted oral medications have very few side effects and patients remain on them for an average of two years, Olugbile says.

In the past five years, genetic testing has become standard of care for some cancers specifically colon, lung and melanoma because those types of cancers tend to have genetic mutations that have been known to respond to therapy, says Sara Patterson, manager of clinical analytics and curation at Jackson Labs, which works with UConn and Yale researchers.But targeted therapy is not a cure-all, and researchers are still a long way from using precision medicine to treat all cancer patients. Even if cancers have the same genomic change and mutation, theres no guarantee they will all respond to the same therapy, she says.Overall, precision medicine is only effective at stopping the spread of cancer in an average of 20 percent of cancer patients treated, Olugbile says, with variations by cancer. Sometimes the cancer returns because the tumor changes to resist the therapy, Patterson adds.

As doctors and researchers do more genomic sequencing, the data pool will grow and so will knowledge of what medications work most effectively against various tumor types.The more information we gather, the better well know how to treat specific patients, Patterson says.

Reimbursement from insurance companies can be a challenge. If precision treatment for a particular type of cancer hasnt been approved by the insurance industry, its difficult to get reimbursed for genomic testing, says Sue Mockus, director of product innovation and strategic commercialization at Jackson Labs.Its a catch-22. Even though a patient with pancreatic cancer could benefit from a targeted therapy, unless that patient is part of a clinical trial that would pay for the genomic testing, the patient would have to pay out of pocket, the annual cost of which can run into the hundreds of thousands of dollars. If you do have a mutation identified and your physician wants to give you the medication off label, you have to fight with the insurance company, Mockus says.

Experts have suggested a value-based approach to precision medicine, reports the International Journal of Public Health. This means policy decisions about reimbursement and investment in research and development will factor in how long patients lives are prolonged and the quality of those lives, the Journal reports.

Oncologists also offer cancer patients immunotherapy, another form of personalized medicine, Patterson says. Theyre using diagnostic tests on tumors, independent of genomic sequencing, to determine if their tumor profiles make them a good immunotherapy candidate. Immunotherapy is approved for multiple tumor types, as long as they have certain markers, she says.

Former President Jimmy Carter became cancer free after receiving radiation and immunotherapy to treat the melanoma that had spread to his brain and liver. While immunotherapy can cure cancer for some, its only effective about 20 percent of the time, Olugbile says. It varies a bit by cancer, with some cancers having a higher success rate, he adds.

Through a collaboration with Memorial Sloan Kettering, Hartford HealthCares Advanced Disease Clinic was scheduled to open this spring to give patients even more options, he says. If targeted therapies and immunotherapies dont work or are not a match for patients, doctors will look for suitable clinical trials that offer potential treatments, Olugbile says.Our goal is to create awareness on two fronts, one is among the doctors. Yes, we are available to help if patients have gone through standard of care who didnt respond, he says. Its also an option for patients who want to be treated with precision medicine closer to home. The goal is to make it available so they dont have to go to New York or Boston, he says. Its right here in Hartford and hopefully at other cancer centers over time.

From Yale, Herbst leads a clinical trial through the National Cancer Institute where he and his team are trying to match the right patient to the right drug.Every tumor is getting sequenced. Thats accelerating the field. The sequencing techniques have gotten cheaper and faster, so we can analyze them at the point of care, Herbst says. This is why clinical trials are so important. Whats a clinical trial today is standard of care tomorrow.

In a study published in the journal Science Translational Medicine, a multi-institutional research team including a Connecticut doctor developed an advanced method to analyze existing data from thousands of clinical trials, comparing which genes FDA-approved drugs work against to the genes active in pediatric brain tumor patients. This sped up the lengthy process of developing cancer drugs.

Dr. Ching Lau, head of the oncology-hematology division at Connecticut Childrens Medical Center and the pediatric oncology-hematology department at UConn School of Medicine, is accessing the World Community Grid, an IBM-funded program that allows researchers worldwide to perform tens of thousands of virtual experiments. Instead of screening thousands and thousands of compounds to try to find a potential drug, we found we could use genomics data already available and do a more systems-approach analysis to figure out the predominant pathways driving the tumor cells, Lau, professor at The Jackson Laboratory, says in an email. Then we asked if there were any existing FDA-approved drugs that could potentially modulate those pathways.

The researchers identified eight drugs that could potentially fight medulloblastoma (MB) tumors, the most common malignant brain tumor in children. One of the drugs showed an increased survival rate in mice with MB tumors, and a clinical trial is being pursued.

Personalized medicineand heart disease

Precision medicines applications have expanded beyond cancer care. At first, much heart disease research relied on a genetic analysis of whether someone was predisposed to a disease. Thanks to a growing database of patient information that is shared worldwide, researchers can mine huge data sets with hundreds of thousands of cases for patterns and abnormalities that lead to discoveries, says Beth Taylor, associate professor of kinesiology at UConn and director of exercise physiology research in cardiology at Hartford Hospital. Researchers and clinicians know that about half the people who have heart attacks dont have the typical risk factors such as high blood pressure, obesity and diabetes. To determine why physically active people with healthy diets have heart attacks, researchers are using precision medicine to comb through large studies to find small predictors, Taylor says. Often the influence of any one factor is hard to detect unless you have a big sample size, she says.

The National Institutes of Health requires grant recipients to share their data to a national registry so that researchers have access to big data, she says. (Personal information such as date of birth, name and address are removed from files used for research studies.)

When we first began to really measure genetic variations, it was believed that was going to be the big hope in treatment, Taylor says. But genes are complex and environmental factors modify genetics for multiple generations.

For the first time ever, weve got wide-scale computing ability to analyze huge data points. This can better allow us to predict disease progression and optimize treatment, she says. Many of us would say that this concept of big data is as or more important than genetic risk. Genetic risks are not the whole picture.

For the first time ever, weve got wide-scale computing ability to analyze huge data points. This can better allow us to predict disease progression and optimize treatment.

Progress with diabetes

Precision medicine is not widely used in the treatment ofdiabetesin the U.S., except when it comes to a rare form of diabetes called neonatal diabetes mellitus. While type 1 and type 2 diabetes are controlled by two or more genesand additional genetic factors,neonatal diabetes mellitus involves a single gene and develops in babies under 6 months old.

Through genetic testing of babies with elevated blood sugar levels,researchers learnedthat about half the patients have gene mutations that respond well to a pill used to treat type 2 diabetes and they dont need to be on insulin for the rest of their lives like type 1 diabetics, says Karel Erion,director of research stewardship and communications for the American Diabetes Association.

When infants show signs of type 1 diabetes at Yale New Haven Childrens Hospital or Connecticut Childrens Medical Center, they are automatically tested for neonatal diabetes, hospital doctors say.

An example of precision medicine as a predictor of disease is the TrialNet database, which uses genetic testing to determine whether the relatives of those with type 1 diabetes have two or more of the five diabetes-related autoantibodies (proteins produced by the immune system directed against the persons own proteins) linked to increased risk of developing type 1 diabetes. Type 1 diabetics must take insulin for the rest of their lives to survive, and theres no known way to prevent the autoimmune disease. Type 1 diabetes, formerly called juvenile diabetes, typically strikes children and adolescents, causing the pancreas to stop producing insulin, a hormone needed to process sugar, or glucose, from food. Type 2 diabetes was formerly known as adult-onset diabetes, but the disorder is being seen in more children, thought to be the result of a rise in childhood obesity. Screening identifies the early stages of the disease years before any symptoms appear, according to the TrialNet website.

In a study published in the New England Journal of Medicine, researchers from the TrialNet Study Group, led by Yale Universitys Dr. Kevan Herold, found that an experimental medication delayed the onset of type 1 diabetes in high-risk participants by two years compared to the control group. The disease was diagnosed in 43 percent of the participants who received the medication, teplizumab, and 72 percent of those who received the placebo.

Alzheimers disease and dementia

Only 1 to 3 percent of the 5 million people living with Alzheimers disease have a genetic mutation that leads to whats called genetic or familial Alzheimers. But one in three older adults will eventually develop some form of dementia, says Rebecca Edelmayer, the Alzheimers Association director of scientific engagement.

Like other diseases that strike large segments of the population, researchers rely on big data to learn about Alzheimers and which genes play a role in who gets it.Researchers have learned that there are several risk factors that contribute to dementia, she says. Specifically, the presence of heart disease, high blood pressure, diabetes, social and cognitive isolation, poor nutrition and the level of education, can contribute to cognitive decline, she says.

Scientists from around the world share research data and draw from data in the Global Alzheimers Association Interactive Network, she says.The field has made some dramatic advances in understanding of how genetics play a role and how other underlying diseases play a role, Edelmayer says. We need to give doctors evidence-based recommendations.

Read the original:
For cancer treatment and more, genetic-based precision medicine holds a lot of promise - Connecticut Magazine

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is establishing a reputation for being one of the best-performing healthcare ETFs, a legacy forged over its multi-year lifespan, not just a few weeks.

One of the driving forces behind ARKGs enviable long-term track records its the managers ability to identify disruptive forces in the healthcare and genomics arenas. The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.

Increasingly, clinicians are tailoring treatments to a patients specific genetic mutations, said ARK analyst Simon Barnett in a recent note. While the number of precision therapies targeting these mutations has grown, only recently have costs dropped to a low enough level that physicians can sequence an individuals genomic profile and identify his or her mutations.

ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed and applied by reducing guesswork and enhancing precision; restructuring health care, agriculture, pharmaceuticals, and enhancing our quality of life.

Empowered by the cost declines of next generation DNA sequencing (NGS), diagnostic providers such as Veracyte (VCYT), Exact Sciences (EXAS), and Guardant Health (GH) are advancing personalized medicine by matching patients to precision therapies. ARK believes that therapeutics companies increasingly will use NGS in clinical trials, creating targeted therapies that ultimately will supplant traditional chemotherapies, writes Barnett.

Guardant Health and Veracyte combine for almost 6% of ARKGs roster.

Bolstering the long-term case for genetic sequencing is the fields ability to help healthcare professionals more accurately diagnose ailments, delivering a higher level of personalized patient care.

In the lucrative oncology field, a prime target for many genomics companies, there are myriad ways genomics and precision medicine can combine to potentially increase positive outcomes for patients.

Some mutations are not inherited and can appear spontaneously, giving rise to aggressive cells that coalesce into tumors. In the case of spontaneous variants, cancer patients are matched to targeted therapies with a lock-and-key system, according to Barnett. First, using molecular diagnostic tests, oncologists search for the mutationthe lockthat is driving tumor growth. Then, diagnostic vendors introduce the molecular information to a genomic biomarker database and search for the best treatmentthe key. Importantly, as the data on clinical outcomes feeds back into the system, the accuracy of the algorithms that match patients to therapies increases continuously.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Excerpt from:
Power of Precision Medicine Could be Fueled Here - ETF Trends

Newswise Lawrenceville, NJ, USAMay 26, 2020Value in Health, the official journal of ISPORthe professional society for health economics and outcomes research, announced today the publication of a series of articles focused on methods for moving from the evaluation of precision medicine into practice and policy. The series was published in the May 2020 issue of Value in Health.

Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle, said Guest Editor Kathryn A. Phillips, PhD, Center for Translational and Policy Research on Personalized Medicine, University of California at San Francisco, San Francisco, CA, USA. This approach allows clinicians and researchers to predict more accurately which treatments and prevention strategies for a particular disease will work in which groups of people.

The themed section highlights next-generation sequencing technologies, which are the fastest-growing type of precision medicine technology. These technologies include panels that test multiple genes for a single indication, whole exome sequencing tests that evaluate the entire exome (coding regions of the genome), and whole genome sequencing tests that evaluate the entire genome.

In her introductory editorial, Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy, Phillips provides historical perspective and introduces the other 5 articles in the series:

Much progress has been made in developing and applying methods to evaluate precision medicine, said Phillips. Nevertheless, new tests such as minimally invasive liquid biopsies and emerging approaches such as artificial intelligence and machine learning platforms will continue to require the development and adaptation of methods used to assess the value of precision medicine. The collective efforts of a society like ISPOR can bring together the wide range of disciplines and stakeholders that will be needed to continue to evolve the methods and approaches used to assess precision medicine.

###

ABOUT ISPORISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.Website | LinkedIn | Twitter (@ispororg) | YouTube | Facebook | Instagram

ABOUT VALUE IN HEALTHValue in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journals 2018 impact factor score is 5.037. Value in Health is ranked 5th of 98 journals in healthcare sciences and services, 4th of 81 journals in health policy and services, and 11th of 363 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.Website | Twitter (@isporjournals)

Go here to see the original:
Moving Precision Medicine From Evaluation Into Practice and Policy - Newswise